About this Research Topic
The goal of this Research Topic is to shed light on clinical research unraveling the relationship between SLE and Sjögren’s. Do patients have more or less frequently specific disease characteristics when these two diseases occur concomitantly? Additionally, to uncover whether Sjögren’s associated autoantibodies or this diagnosis changes outcomes in SLE patients and how the presence of anti-dsDNA antibodies or an SLE diagnosis modifies Sjögren’s disease features. We want to motivate researchers to investigate potential biomarkers and molecular pathways that might elucidate the complex interplay between SLE and Sjögren's, contributing to a deeper understanding of their co-occurrence and its implications on disease manifestations and treatment strategies.
In recent decades we have witnessed remarkable strides in the realm of clinical research and treatment for Systemic Lupus Erythematosus (SLE) and Sjögren’s disease. In fact, SLE and Sjögren’s disease have been vastly studied as independent diseases. Although there are still unmet needs in our knowledge of disease mechanisms, organ involvement predictive factors and foremost effective treatment options for both diseases individually, is a major area that lacks answers concerning patients with both diagnoses. Autoantibodies often associated with Sjögren’s such as anti-SSA (Ro) and anti-SSB (La), have been found in SLE patients, with some reports unable to find an association with specific clinical features of Sjögren’s disease. Conversely, anti-double-stranded DNA antibody (anti-dsDNA) can also be positive in Sjögren’s patients without clinical significance.
This team’s initiative is to lead and oversee this initiative, with emphasis on recent advancements, ongoing obstacles, and prospective developments within this field, with submissions expected to align with the defined scope of both the Research Topic and the Journal.
This Research Topic will accept Original Research, Systematic Reviews, Reviews, Case Reports, Data Reports, and Brief Research Reports.
In recent decades we have witnessed remarkable strides in the realm of clinical research and treatment for Systemic Lupus Erythematosus (SLE) and Sjögren’s disease. In fact, SLE and Sjögren’s disease have been vastly studied as independent diseases. Although there are still unmet needs in our knowledge of disease mechanisms, organ involvement predictive factors and foremost effective treatment options for both diseases individually, is a major area that lacks answers concerning patients with both diagnoses. Autoantibodies often associated with Sjögren’s such as anti-SSA (Ro) and anti-SSB (La), have been found in SLE patients, with some reports unable to find an association with specific clinical features of Sjögren’s disease. Conversely, anti-double-stranded DNA antibody (anti-dsDNA) can also be positive in Sjögren’s patients without clinical significance.
This team’s initiative is to lead and oversee this initiative, with emphasis on recent advancements, ongoing obstacles, and prospective developments within this field, with submissions expected to align with the defined scope of both the Research Topic and the Journal.
This Research Topic will accept Original Research, Systematic Reviews, Reviews, Case Reports, Data Reports, and Brief Research Reports.
Keywords: SLE, Sjogren, Sjogren's disease, secondary Sjogren, outcomes, Systemic Lupus Erythematosus, concomitant diseases, polyautoimmunity
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
